Advertisement
Commentary| Volume 21, P117-119, April 2018

Commentary on: Comparing the efficacy of disease-modifying therapies in multiple sclerosis

Published:March 15, 2018DOI:https://doi.org/10.1016/j.msard.2018.03.010
Commentary on: Comparing the efficacy of disease-modifying therapies in multiple sclerosis
Previous ArticleOnline validation of the Italian version of the patient determined disease steps scale (PDDS) in people with multiple sclerosis
Next ArticleReply to Tsivgoulis and colleagues comments
      We read with interest the recently published review article in Multiple Sclerosis and Related Disorders comparing the efficacy of disease-modifying therapies (DMTs) in multiple sclerosis (MS) by Dr. Mitsikostas and Dr. Goodin (
      • Mitsikostas D.D.
      • Goodin D.S.
      Comparing the efficacy of disease-modifying therapies in multiple sclerosis.
      Mult. Scler. Relat. Disord. 2017; 18: 109-116
      ). During the inspection of the presented Figures and Tables in the article we noticed some inaccuracies, which inevitably raised important questions about the methodology, data analysis and result interpretation.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Multiple Sclerosis and Related Disorders
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • Christensen P.M.
        • Kristiansen I.S.
        Number-needed-to-treat (NNT)--needs treatment with care.
        Basic Clin. Pharmacol. Toxicol. 2006; 99: 12-16
        View in Article
        • Cook R.J.
        • Sackett D.L.
        The number needed to treat: a clinically useful measure of treatment effect.
        BMJ. 1995; 310: 452-454
        View in Article
        • DerSimonian R.
        • Laird N.
        Meta-analysis in clinical trials.
        Control Clin. Trials. 1986; 7: 177-188
        View in Article
        • Hutton J.L.
        Number needed to treat: properties and problems.
        J. R. Stat. Soc. A. 2000; 163: 403-419
        View in Article
        • Hutton J.L.
        Misleading statistics: the problems surrounding number needed to treat and number needed to harm.
        Pharm. Med. 2010; 24: 145-149
        View in Article
        • McAlister F.A.
        The "number needed to treat" turns 20--and continues to be used and misused.
        CMAJ. 2008; 179: 549-553
        View in Article
        • Mitsikostas D.D.
        • Goodin D.S.
        Comparing the efficacy of disease-modifying therapies in multiple sclerosis.
        Mult. Scler. Relat. Disord. 2017; 18: 109-116
        View in Article
        • Rudick R.A.
        • Stuart W.H.
        • Calabresi P.A.
        • et al.
        Natalizumab plus interferon beta- 1a for relapsing multiple sclerosis.
        N. Engl. J. Med. 2006; 354: 911-923
        View in Article
        • Stang A.
        • Poole C.
        • Bender R.
        Common problems related to the use of number needed to treat.
        J. Clin. Epidemiol. 2010; 63: 820-825
        View in Article
        • Tramacere I.
        • Del Giovane C.
        • Salanti G.
        • D'Amico R.
        • Filippini G.
        Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis.
        Cochrane Database Syst. Rev. 2015; : CD011381
        View in Article
        • Tsivgoulis G.
        • Katsanos A.H.
        • Grigoriadis N.
        • et al.
        The effect of disease modifying therapies on disease progression in patients with relapsing-remitting multiple sclerosis: a systematic review and meta-analysis.
        PLoS One. 2015; 10: e0144538
        View in Article

      Article info

      Publication history

      Published online: March 15, 2018
      Accepted: March 14, 2018
      Received: December 9, 2017

      Identification

      DOI: https://doi.org/10.1016/j.msard.2018.03.010

      Copyright

      © 2018 Published by Elsevier B.V.

      ScienceDirect

      Access this article on ScienceDirect

      The content on this site is intended for healthcare professionals.


      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the Cookie Preference Center for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties.


      RELX